Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications
Mechanisms of action of potential ncRNA-based immunotherapeutics. Several ncRNA-centered immunotherapies have been developed. The TGF-β1/SMAD3 signaling pathway can inhibit the expression of T-bet and IFN-γ, thereby blunting NK cell activity. CD56-NP-miR-186 improves NK cytotoxicity by targeting TGFBR1 and TGFBR2. siPD-L1@PLGA suppresses IFN-γ-mediated PD-L1 induction and induces local expansion of CD8+ T cells. pCD28-siRNA-PD-1 can increase CD28 expression and reduce PD-1 expression. It also induces antitumor immune responses by increasing the populations of CD4+ T cells and CD8+ T cells while repressing Treg expansion. EVs/siCD38 impedes CD38-mediated adenosine generation and facilitates macrophage repolarization toward tumor-suppressive M1-like phenotype. CD.siRNA.stearic acid-PEG-SA induces the reprograming of M2 macrophages to M1 phenotype by silencing CSF-1R. These ncRNA-based approaches can reverse cancer resistance to conventional immunotherapies and hold great promise for the clinical use in cancer treatment. IFN-γ, interferon-γ; TGFBR1, transforming growth factor-β receptor 1; TGFBR2, transforming growth factor-β receptor 2; NK cell, natural killer cell; Treg, regulatory T cell; TGF-β1, transforming growth factor-β1; IFNγR, interferon-γ receptor; PD-L1, programmed cell death-ligand 1; PD-1, programmed cell death protein-1; MDSC, myeloid-derived suppressive cell; TAM, tumor-associated macrophage; CSF-1R, colony stimulating factor-1 receptor.
Publication
Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications. (2023) Man Wang, et al. Front Immunol. 2023;14:1268745. Figure: F7.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | CD4+ | CD4 | ncbigene_symbol | CD4 | 920 |
| Homo sapiens | Primates | CD8+ | CD8 | ncbigene_synonym | CD8A | 925 |
| Homo sapiens | Primates | CD8+ | CD8 | famplex_relations | CD8B | 926 |
| Homo sapiens | Primates | TAM | TAM | ncbigene_symbol | TAM | 8205 |
| Homo sapiens | Primates | TAM | TAM | ncbigene_synonym | STIM1 | 6786 |
| Homo sapiens | Primates | T-bet | T-BET | ncbigene_synonym | TBX21 | 30009 |
| Homo sapiens | Primates | TGFBR1- | TGFBR1 | ncbigene_symbol | TGFBR1 | 7046 |
| Homo sapiens | Primates | CD56 | CD56 | ncbigene_synonym | NCAM1 | 4684 |
| Homo sapiens | Primates | TGFBR2 | TGFBR2 | ncbigene_symbol | TGFBR2 | 7048 |
| Homo sapiens | Primates | CD28 | CD28 | ncbigene_symbol | CD28 | 940 |
| Homo sapiens | Primates | TGF-B1 | TGF-B1 | ncbigene_synonym | TGFB1 | 7040 |
| Homo sapiens | Primates | CD38 | CD38 | ncbigene_symbol | CD38 | 952 |
| Homo sapiens | Primates | IFNYR | IFNGR | ncbigene_synonym | IFNGR1 | 3459 |
| Homo sapiens | Primates | PD-L1 | PD-L1 | ncbigene_synonym | CD274 | 29126 |
| Homo sapiens | Primates | CSF-1R! | CSF1R | ncbigene_symbol | CSF1R | 1436 |
| Homo sapiens | Primates | PD-1 | PD-1 | ncbigene_synonym | PDCD1 | 5133 |
| Homo sapiens | Primates | PD-1 | PD-1 | ncbigene_synonym | RPL17 | 6139 |
| Homo sapiens | Primates | PD-1 | PD-1 | ncbigene_synonym | RPL17-C18orf32 | 100526842 |
| Homo sapiens | Primates | CD169 | CD169 | ncbigene_synonym | SIGLEC1 | 6614 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| PLGA | NA | mesh:C043435 | ||
| stearic acid | NA | mesh:D013229 | ||
| PEG | NA | mesh:C499599 | ||
| TAM | NA | mesh:C419191 | ||
| Adenosine | Adenosine | mesh:D000241 | adenosine | chebi:16335 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|---|---|---|---|
| Cancer | NA | mesh:D009369 |